Tagged with Ipsen,

Global Two years into his role, Ipsen’s EVP and Chief Medical Officer Prof. Dr. med. Steven Hildemann MD discusses his vision of patient-centricity and how he is leading a medical transformation that puts data-driven insights at the core and aims to make a real difference to both clinical practice and patients’…

France French mid-cap pharma Ipsen achieved total sales of EUR 2.869 billion in 2021, a 12.3 percent increase on results from the pandemic-affected 2020 total. The company also announced plans to divest its consumer healthcare business – which currently accounts for around eight percent of total revenues – to fellow French…

Global Speaking from Ipsen’s US headquarters in Cambridge, Massachusetts off the back of a whirlwind first 16 months as the firm’s Chief Business Officer, Philippe-Lopes Fernandes outlines his deal-making philosophy, how the iconic French mid-cap represents a reliable partner for innovative biotechs looking to establish a global reach for their programs,…

France The latest news from French pharma, including AI-based biotech Owkin’s new status as a USD one billion-valued unicorn following fresh investment from Sanofi. Also included is another deal for Sanofi, this time in the form of a partnership with Chinese tech giant Baidu to use its algorithm for mRNA sequencing.…

Saudi Arabia Ipsen’s general manager for Middle East and Africa (MEA), Khaled Elrefae, highlights the French firm’s expanding footprint in the region, the fundamentals that make MEA a growth driver for Ipsen, and the opportunities for further growth from its oncology, rare disease and neuroscience portfolios. In addition, Elrefae discusses the changing…

France The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19 vaccine as it faces delays with its in-house product and the impact of this on the country’s global scientific standing. Also featured are the rising problem of anti-vaccine sentiment, an exclusive…

Global In a wide-ranging and exclusive interview with PharmaBoardroom, Ipsen CEO David Loew looks back on an atypical first 100 days at the helm of the iconic French mid-cap; its EUR 3 billion war chest for bolt-on acquisitions; planned expansions in rare- and ultra-rare diseases; and the niche oncology segments where…

Global Ipsen CEO David Loew took aim at the lip service often paid to the notion of ‘patient-centricity’ in pharma in conversation at the FT’s Global Pharmaceutical and Biotechnology Conference last week and explained how the industry should take on a wider and deeper role in shaping healthcare systems, thereby creating…

France A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how Ipsen has managed to achieve sales growth in 2020 despite the pandemic, diagnostics biotech Novacyt’s remarkable rise, and a new job for former Ipsen boss Marc de Garidel.   Sanofi aims for COVID-19…

France A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s new Chinese acquisition catapults it into the world’s top 5 CDMOs, Ipsen’s resilient performance in the first half of 2020 despite COVID-19 headwinds, and the French government’s push for more domestic pharma manufacturing.…

France David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed CEO of fellow French firm Ipsen on the 28th May 2020, effective 1st July.   Loew, who spoke to PharmaBoardroom in January 2019 while in position at Sanofi Pasteur, is taking the helm from Aymeric Le…

Long Read Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on chasing demand in the decidedly more populous Asian market space. But, with an estimated annual growth rate of 10 percent,…